|
Evaxion Biotech A/S (EVAX): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Evaxion Biotech A/S (EVAX) Bundle
In the cutting-edge world of biotechnology, Evaxion Biotech A/S emerges as a pioneering force, leveraging artificial intelligence to revolutionize personalized immunotherapy. With its innovative AI-powered platform targeting cancer and infectious diseases, the Danish company is pushing the boundaries of precision medicine, transforming how we approach therapeutic development through advanced computational algorithms and a strategic global approach. Dive into the comprehensive marketing mix that reveals how this dynamic biotech innovator is positioning itself to potentially reshape the future of medical treatments.
Evaxion Biotech A/S (EVAX) - Marketing Mix: Product
AI-Powered Precision Immunotherapy Platform
Evaxion Biotech develops AI-driven immunotherapy solutions targeting cancer and infectious diseases. The company's proprietary AI platform enables computational design of personalized vaccine and immunotherapy candidates.
| Platform Technology | Key Capabilities |
|---|---|
| AI Immunology Algorithms | Machine learning-based antigen identification |
| Computational Design | Personalized vaccine candidate generation |
| Predictive Modeling | Immune response prediction |
Clinical-Stage Pipeline Products
Evaxion's product portfolio focuses on two primary therapeutic domains:
- Oncology immunotherapies
- Infectious disease vaccines
| Product | Disease Target | Development Stage |
|---|---|---|
| EVX-01 | Melanoma | Phase 1/2 Clinical Trial |
| EVX-02 | Solid Tumors | Preclinical Development |
| EVX-03 | Infectious Diseases | Research Stage |
Computational Drug Discovery Approach
Evaxion utilizes advanced AI algorithms for comprehensive drug discovery and design processes.
- Machine learning-based antigen identification
- Predictive immune response modeling
- Personalized vaccine candidate generation
Evaxion Biotech A/S (EVAX) - Marketing Mix: Place
Headquarters Location
Evaxion Biotech A/S is headquartered at Kogle Allé 4, 2970 Hørsholm, Denmark.
Research and Development Operations
Research and development operations are concentrated in the Scandinavian region, specifically in Denmark.
| Location | Operational Focus | Geographic Scope |
|---|---|---|
| Hørsholm, Denmark | Primary R&D Center | Scandinavian Region |
Global Collaboration Strategy
Key Pharmaceutical and Research Partnerships
- United States research institutions
- European pharmaceutical networks
- International immunotherapy research centers
Target Markets
| Market | Market Penetration Strategy | Primary Focus |
|---|---|---|
| United States | Direct pharmaceutical market engagement | Immunotherapy development |
| European Markets | Collaborative research partnerships | AI-driven drug discovery |
Distribution Channels
- Direct sales to pharmaceutical companies
- Research collaboration platforms
- International biotechnology conferences
Evaxion Biotech A/S (EVAX) - Marketing Mix: Promotion
Scientific Conference Presentations and Academic Publications
Evaxion Biotech A/S actively participates in scientific conferences to showcase its AI-driven immunotherapy research. In 2023, the company presented at the following key conferences:
| Conference | Date | Location | Presentation Focus |
|---|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | Orlando, FL | AI-powered vaccine development |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | San Diego, CA | Precision immunotherapy platforms |
Investor Relations Communications
Evaxion Biotech utilizes multiple communication channels for investor outreach:
- Quarterly earnings reports filed with NASDAQ
- Press releases distributed through Business Wire
- Investor presentations with 4 quarterly updates in 2023
| Communication Type | Frequency | Platform |
|---|---|---|
| Earnings Calls | 4 times per year | NASDAQ Investor Relations Portal |
| Press Releases | 12 releases in 2023 | Business Wire |
Digital Marketing Channels
Evaxion maintains a comprehensive digital presence:
- Company website: evaxion-ai.com
- LinkedIn Company Page followers: 3,421 as of January 2024
- Twitter followers: 1,872 as of January 2024
Partner and Investor Outreach
Strategic engagement with potential pharmaceutical partners and investors includes:
- Targeted pharmaceutical partnership meetings: 6 in 2023
- Investor roadshow presentations: 3 in 2023
- Biotech investment conferences attended: 2 in 2023
| Outreach Activity | Number in 2023 | Target Audience |
|---|---|---|
| Pharmaceutical Partnership Meetings | 6 | Potential Pharma Collaborators |
| Investor Roadshow Presentations | 3 | Institutional Investors |
Evaxion Biotech A/S (EVAX) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Evaxion Biotech A/S operates as a pre-revenue biotechnology company with the following financial characteristics:
| Financial Metric | Value |
|---|---|
| Market Capitalization | $25.6 million |
| Cash and Cash Equivalents | $14.3 million |
| Net Loss (2023 Fiscal Year) | $12.7 million |
| Stock Price (NASDAQ: EVAX) | $1.47 per share |
Funding Strategy
Evaxion's pricing strategy is primarily focused on research and development funding through multiple channels:
- Venture Capital Investments
- Public Market Financing
- Research Grants
- Potential Collaborative Research Agreements
Funding Sources
| Funding Source | Amount Raised | Year |
|---|---|---|
| Venture Capital | $8.5 million | 2023 |
| Public Offering | $6.2 million | 2023 |
| Research Grants | $1.6 million | 2023 |
Pricing Approach
Current pricing strategy is centered on potential future value of therapeutic pipeline, with focus on:
- Immunotherapy development
- AI-driven drug discovery platforms
- Potential licensing of proprietary technologies
Stock Performance Metrics
| Performance Indicator | Value |
|---|---|
| 52-Week Low | $0.85 |
| 52-Week High | $2.15 |
| Average Trading Volume | 125,000 shares |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.